(NASDAQ: UNCY) Unicycive Therapeutics's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 83.05%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.65%.
Unicycive Therapeutics's revenue in 2025 is $0.On average, 1 Wall Street analysts forecast UNCY's revenue for 2025 to be $73,119,430, with the lowest UNCY revenue forecast at $73,119,430, and the highest UNCY revenue forecast at $73,119,430. On average, 4 Wall Street analysts forecast UNCY's revenue for 2026 to be $3,238,395,960, with the lowest UNCY revenue forecast at $695,870,901, and the highest UNCY revenue forecast at $8,789,344,010.
In 2027, UNCY is forecast to generate $11,895,506,837 in revenue, with the lowest revenue forecast at $7,134,619,524 and the highest revenue forecast at $20,106,077,003.